Close

Alexion Pharma (ALXN) Says Data from Global aHUS Registry Shows Reduced Risk with Soliris

Go back to Alexion Pharma (ALXN) Says Data from Global aHUS Registry Shows Reduced Risk with Soliris

New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating SolirisĀ® (eculizumab) Treatment Prior to Transplant Compared to

November 17, 2016 5:32 PM EST

- Reduction in Incidence of Chronic Dialysis was also Observed in Patients Initiating Soliris Treatment Prior to Transplant -

- Reduction in Dialysis was Sustained Post-Transplant with Ongoing Treatment -

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that researchers presented new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that initiation of Soliris® (eculizumab) prior to kidney transplant reduces the risk of dialysis post-transplant in patients with aHUS. Specifically, results showed that starting... More